Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Draft genome sequence of the strain 16-537536, isolated from a patient with bronchiectasis and its relationship to the Pseudomonas koreensis group of the Pseudomonas fluorescens complex.

Fluit AC, Rogers MRC, Díez-Aguilar M, Cantón R, Benaissa-Trouw BJ, Bayjanov JR, Ekkelenkamp MB.

BMC Res Notes. 2020 Jan 6;13(1):10. doi: 10.1186/s13104-019-4863-2.

2.

Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Ekkelenkamp MB, Cantón R, Díez-Aguilar M, Tunney MM, Gilpin DF, Bernardini F, Dale GE, Elborn JS, Bayjanov JR, Fluit A.

Antimicrob Agents Chemother. 2020 Jan 27;64(2). pii: e01541-19. doi: 10.1128/AAC.01541-19. Print 2020 Jan 27.

PMID:
31767727
3.

Whole-genome analysis of Pandoraea species strains from cystic fibrosis patients.

Bayjanov JR, Ekkelenkamp MB, Rogers MR, Cantón R, Benaissa-Trouw BJ, Díez-Aguilar M, Tunney M, Fluit AC.

Future Microbiol. 2019 Nov;14:1357-1367. doi: 10.2217/fmb-2019-0038. Epub 2019 Nov 25.

PMID:
31762328
4.

Mechanisms of action and antimicrobial activity of ceftobiprole.

Morosini MI, Díez-Aguilar M, Cantón R.

Rev Esp Quimioter. 2019 Sep;32 Suppl 3:3-10. Review.

5.

Hypermucoviscous Klebsiella pneumoniae: A challenge in community acquired infection.

Sánchez-López J, García-Caballero A, Navarro-San Francisco C, Quereda C, Ruiz-Garbajosa P, Navas E, Dronda F, Morosini MI, Cantón R, Diez-Aguilar M.

IDCases. 2019 May 3;17:e00547. doi: 10.1016/j.idcr.2019.e00547. eCollection 2019.

6.

New microbiological aspects of fosfomycin.

Díez-Aguilar M, Cantón R.

Rev Esp Quimioter. 2019 May;32 Suppl 1:8-18. Review.

7.

Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.

Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Merino I, de Dios Caballero J, Jones M, van Westreenen M, Tunney MM, Cantón R, Fluit AC.

Int J Antimicrob Agents. 2019 Jan;53(1):84-88. doi: 10.1016/j.ijantimicag.2018.09.001. Epub 2018 Sep 19.

PMID:
30240837
8.

Susceptibility testing and detection of β-lactam resistance mechanisms in Enterobacteriaceae: a multicentre national proficiency study.

Díez-Aguilar M, Conejo MC, Morosini MI, Tormo Palop N, Gimeno C, Cantón R, Pascual Á.

Int J Antimicrob Agents. 2018 Apr;51(4):612-619. doi: 10.1016/j.ijantimicag.2017.12.008. Epub 2017 Dec 21.

PMID:
29274802
9.

Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.

Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01650-17. doi: 10.1128/AAC.01650-17. Print 2018 Jan.

10.

Microbiological diagnosis of biofilm-related infections.

Macià MD, Del Pozo JL, Díez-Aguilar M, Guinea J.

Enferm Infecc Microbiol Clin. 2018 Jun - Jul;36(6):375-381. doi: 10.1016/j.eimc.2017.04.006. Epub 2017 May 27. Review. English, Spanish.

PMID:
28558916
11.

[Dalbavancin breakpoints and recommendations for in vitro study of its activity].

Cantón R, Díez-Aguilar M, Morosini MI.

Enferm Infecc Microbiol Clin. 2017 Jan;35 Suppl 1:15-21. doi: 10.1016/S0213-005X(17)30030-7. Spanish.

PMID:
28129815
12.

Is a New Standard Needed for Diffusion Methods for In Vitro Susceptibility Testing of Fosfomycin against Pseudomonas aeruginosa?

Díez-Aguilar M, Martínez-García L, Cantón R, Morosini MI.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1158-61. doi: 10.1128/AAC.02237-15. Print 2016 Feb.

13.

Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.

Díez-Aguilar M, Morosini MI, Tedim AP, Rodríguez I, Aktaş Z, Cantón R.

Antimicrob Agents Chemother. 2015 Oct;59(10):6039-45. doi: 10.1128/AAC.00822-15. Epub 2015 Jul 20.

14.

Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes.

Díez-Aguilar M, Morosini MI, López-Cerero L, Pascual Á, Calvo J, Martínez-Martínez L, Marco F, Vila J, Ortega A, Oteo J, Cantón R.

J Antimicrob Chemother. 2015 Aug;70(8):2306-10. doi: 10.1093/jac/dkv088. Epub 2015 Apr 21.

PMID:
25900161
15.

Patients infected with HIV are at high-risk for hepatitis E virus infection in Spain.

Mateos-Lindemann ML, Diez-Aguilar M, Galdamez AL, Galán JC, Moreno A, Pérez-Gracia MT.

J Med Virol. 2014 Jan;86(1):71-4. doi: 10.1002/jmv.23804. Epub 2013 Oct 17.

PMID:
24136591
16.

In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method.

Díez-Aguilar M, Morosini MI, del Campo R, García-Castillo M, Zamora J, Cantón R.

Antimicrob Agents Chemother. 2013 Nov;57(11):5701-3. doi: 10.1128/AAC.00589-13. Epub 2013 Aug 12.

17.

[Acute, chronic and fulminant hepatitisE: seven years of experience (2004-2011)].

Mateos-Lindemann ML, Diez-Aguilar M, González-Galdamez A, Graus-Morales J, Moreno-Zamora A, Perez-Gracia MT.

Enferm Infecc Microbiol Clin. 2013 Nov;31(9):595-8. doi: 10.1016/j.eimc.2013.03.014. Epub 2013 Apr 30. Spanish.

PMID:
23642282
18.

Non-diphtheriae Corynebacterium species: an emerging respiratory pathogen.

Díez-Aguilar M, Ruiz-Garbajosa P, Fernández-Olmos A, Guisado P, Del Campo R, Quereda C, Cantón R, Meseguer MA.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):769-72. doi: 10.1007/s10096-012-1805-5. Epub 2012 Dec 28.

PMID:
23271676

Supplemental Content

Loading ...
Support Center